IPG Photonics: Four Straight Double-Digit Quarters, Priced Like a Warning

The growth is real, but it is program-shaped, the margin beat was a tariff refund, and the battery engine management spent a year building just coughed in China

IPGP · Earnings Call · 2026-11-03

The tape disagrees with the transcript

On the page, IPG's third quarter was the best stretch the company has strung together in years: revenue of $288 million, up 15% year over year and 3% sequentially, “the fourth consecutive quarter of double digit revenue growth” — Mark Milton Gitin, Chief Executive Officer · 2026-11-03, adjusted EPS of $0.61 and adjusted EBITDA of $52 million — both at the top of the range — book-to-bill of roughly 1, and $926 million of cash against zero debt. The stock is down 33% over the last 90 days and 37% from its June 30 peak of $117.32. Since the January 2018 high of $263.34 it is still down 72%. That gap — record operating momentum, collapsing share price — is the story. Something in this report tells the market that the good numbers were borrowed from the future, and two things do: where the growth came from, and what the margin beat was made of.

Two engines, both program-shaped

Advanced Solutions rose 33% year over year and 15% sequentially. The two drivers were semiconductors, where revenue more than doubled, and defense, where IPG shipped most of the Lockheed Martin Crossbow order. That second one is the tell: the remaining shipments land in Q4, which means Q4 gets the tailwind's final gasp and the first quarter of 2027 inherits nothing from it. This is the structural problem with the advanced narrative — it is a collection of programs, not a base. Mark Gitin is candid about the size: “this is a smaller piece, but you can see that we have now doubled that year over year” — Mark Milton Gitin, Chief Executive Officer · 2026-11-03. And that fastest-growing bucket is explicitly levered to data centers, GPUs and high bandwidth memory — precisely the cluster the tape is de-rating hardest right now. Across the 30-day window, high power laser names (IPGP included), co-packaged optics and high bandwidth memory sit among the deepest decliners in the market; semiconductor capital equipment is down double digits too. IPG is growing fastest exactly where the market is paying least. Defense is the mirror image: the global tape genuinely likes the theme, with solid rocket motors, missile defense and space-based interceptors among the top 30-day advancers, and reporting peers like DRS flagging themselves as a leading high energy laser provider. So the strategic logic of Crossbow is sound, and the new longer-range SE variant for larger drone classes is a sensible extension. It just doesn't fix lumpiness — one customer's purchase order is not a revenue base.

The battery engine coughs

For at least four quarters, the battery welding pitch was the most reliable part of the story: high-current busbars, thick foil, weld monitoring, rising EV penetration, and above all stationary storage as the underappreciated second leg. In August it was still ascending — “what's becoming a bigger piece of this now is actually stationary storage, which is being driven by data centers for AI” — Mark M. Gitin, Chief Executive Officer and Director · 2026-08-04. Three months later, the tone reversed:

After strong growth, over the last several quarters, we are seeing some moderation, as mentioned, in the China battery capacity additions. We see that as a near term effect.
Mark Milton Gitin, Chief Executive Officer · 2026-11-03

Management frames this as timing, and the long-term logic — grids, EVs, data-center backup — is not wrong. But note how the language has changed and how stationary storage flipped from the company's fastest-rising theme to outright momentum decline in the span of a single quarter. That is the "what changed" of this report. The industrial core that was supposed to be the durable half is now the half that needs a caveat in the guidance paragraph.

The margin beat was a refund

Adjusted gross margin of 41% came in above the top of guidance — aided by $5 million of net tariff refunds worth roughly 170 basis points. Strip them out and you get about 39.3%, which is essentially where the business has been running. And the fourth quarter explicitly excludes the windfall: “adjusted gross margin is expected to be between 37% to 40% as we are not anticipating a meaningful benefit from tariff refunds” — Timothy V. Mammen, Senior Vice President and CFO · 2026-11-03. Timothy Mammen's own bridge confirms the beat was arithmetic, not improvement: the 38.5% midpoint "ties right in" with the ex-refund 39.3% once you account for a slightly lower revenue midpoint of $280 million. A tariff refund is also the least proprietary tailwind available this quarter — ACCO, A.O. Smith, Henry Schein, O'Reilly and Keurig all booked one. Useful for a headline beat; useless as a signal. Which makes the margin promise worth scrutinising against its own history. Last November, the mid-40s structural target was framed with tariffs as "the only real headwind... 150 basis points or so." By August: “with those initiatives gaining momentum over the second half of the year and into 2027, we're continuing to target improvements in gross margin” — Timothy P.V. Mammen, Chief Financial Officer and Senior Vice President · 2026-08-04. Yesterday: several hundred basis points of gain that “should materialize in 2027” — Timothy V. Mammen, Senior Vice President and CFO · 2026-11-03. The date slips a year, the wording barely moves. The numbers explain why the market discounts it. The last filed quarter carried $279 million of revenue, against $382 million at the 2018Q2 peak — and gross margin of 40.4% versus a 57.1% peak. Strip out the recovery and you are left paying 181 times net income for a 4.5% operating margin. What cushions that is the balance sheet: $1.2 billion of effective net cash, no debt, and just 12% liabilities to assets.

What's left

Medical, the other pillar, grew only slightly year over year and improved sequentially. The organic doubling argument has quietly become an M&A argument — the acquisition of LumiBird Medical closes in the fourth quarter, is guided to be accretive in 2027, and expands the addressable market toward $2 billion. That is a legitimate answer, but it is a different answer than the urology roadmap that has been doubling the business verbally since at least late 2025 — “growing our urology revenue kind of 2 to 3x in the next 2 to 3 years” — Mark Gitin, Chief Executive Officer (CEO) · 2025-11-04 was the refrain a year ago, and it is still the refrain. So: a company whose industrial core is decelerating in its most important geography, whose growth is being carried by two programme-shaped buckets, whose margin beat was a refund, and whose stock has already decided the next twelve months of estimates deserve a haircut. March 2, 2027, in New York, is where that gets either re-based or re-rated.